BioCentury | Jul 2, 2007

Calling card put away

When GlaxoSmithKline gained an exclusive option in 2004 to all of Theravance's programs through August 2007, the initial worry among investors was that THRX had become a hostage to the pharma giant. That turned out...
BC Extra | Jun 29, 2007
Financial News

EndoCeutics pulls IPO

EndoCeutics (Quebec City, Quebec) withdrew its IPO, citing market conditions and undisclosed changes made to its clinical trials schedule. In May, the company said it would start a Phase III trial next half of lead...
BioCentury | May 14, 2007

Ebb & Flow

A few cancer vaccine companies and insiders managed to capitalize on rising share prices during the brief window between the March 29 FDA panel vote in favor of Dendreon's Provenge sipuleucel-T for prostate cancer and...
BC Extra | May 12, 2007
Financial News

EndoCeutics amends IPO

EndoCeutics (Quebec City, Quebec) lowered the proposed price range of its IPO and now hopes to sell 5.8 million shares at $7-$9 instead of $11-$13 in an offering on NASDAQ. An $8 price would raise...
BC Extra | Mar 1, 2007
Financial News

EndoCeutics files for IPO

Hormone therapy company EndoCeutics (Quebec City, Quebec) filed to raise up to $75 million in an IPO on NASDAQ underwritten by First Albany; Oppenheimer; and Stifel, Nicolaus. In 2H07, EndoCeutics plans to start a Phase...
Items per page:
1 - 5 of 5